Protocol Review and Monitoring System

摘要-协议审查和监测系统 罗伯特·H·卢里综合癌症中心方案审查和监测系统(PRMS) (LCC)属于科学审查委员会(SRC)的职权范围，该委员会是 构成LCC的研究监督计划。此后，LCC的PRMS不断获得NCI的批准 1998年。SRC是一个多学科委员会，由一个核心成员小组组成，提供必要的 临床肿瘤学研究的主要学科的专业知识，以及来自LCC的代表的专业知识 定量数据科学核心(包括生物统计学)、翻译研究、行为与健康 科学和药剂学团体。SRC由A.B.Benson III，MD担任主席，A.Rademaker联合担任主席。 博士和J.Sosman医学博士(本授权期的新成员)。SRC的重点是与癌症相关的临床回顾。 科学价值、优先顺序和监测科学进展的试验。SRC有权批准 符合该中心的科学价值和科学优先事项的方案，并终止不符合 展示足够的科学进步。在这个赠款周期中所做的改进包括增强了作用 对于疾病团队在协议优先顺序和监测方面，改善了研究之间的沟通 监督委员会和临床试验办公室，以及扩大SRC的代表性 会员制。

ABSTRACT – PROTOCOL REVIEW AND MONITORING SYSTEM The Protocol Review and Monitoring System (PRMS) of the Robert H. Lurie Comprehensive Cancer Center (LCC) falls under the purview of the Scientific Review Committee (SRC), one of several committees that comprise LCC's research oversight program. The LCC's PRMS has received continuous NCI approval since 1998. The SRC is a multidisciplinary committee that consists of a core group of members providing the necessary expertise in the principal disciplines of clinical oncology research, with expertise of representatives from LCC's Quantitative Data Sciences Core (which includes biostatistics), Translational Research, Behavioral and Health Sciences, and Pharmacy groups. The SRC is chaired by A. B. Benson III, MD, and co-chaired by A. Rademaker, PhD, and J. Sosman, MD (new in this grant period). The focus of the SRC is the review of cancer relevant clinical trials for scientific merit, prioritization, and monitoring scientific progress. The SRC has the authority to approve protocols that meet the scientific merit and scientific priorities of the center and to terminate protocols that do not demonstrate sufficient scientific progress. Improvements made over this grant cycle include an enhanced role for Disease Teams in protocol prioritization and monitoring, improved communication among the research oversight committees and with the Clinical Trials Office, as well as broadened representation of SRC membership.